{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:33:18Z","timestamp":1789990398760,"version":"4.0.1"},"publisher-location":"Cham","reference-count":109,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319914381","type":"print"},{"value":"9783319914398","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-91439-8_12","type":"book-chapter","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T20:25:48Z","timestamp":1533155148000},"page":"243-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Idelalisib"],"prefix":"10.1007","author":[{"given":"Katja","family":"Zirlik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"1","key":"12_CR1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Avvaru P, Furqan M, Song Y, Liu D (2013) Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 6(1):88","journal-title":"J Hematol Oncol"},{"issue":"2","key":"12_CR2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.18632\/oncotarget.426","volume":"3","author":"L Alinari","year":"2012","unstructured":"Alinari L, Christian B, Baiocchi RA (2012) Novel targeted therapies for mantle cell lymphoma. Oncotarget 3(2):203\u2013211","journal-title":"Oncotarget"},{"key":"12_CR3","doi-asserted-by":"crossref","unstructured":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI) (2016) A meta-analysis of individual patient data. Lancet Oncol 17(6):779\u2013790","DOI":"10.1016\/S1470-2045(16)30029-8"},{"issue":"9","key":"12_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11912-017-0620-7","volume":"19","author":"JE Arnason","year":"2017","unstructured":"Arnason JE, Brown JR (2017) Targeting B cell signaling in chronic lymphocytic leukemia. Curr Oncol Rep 19(9):61","journal-title":"Curr Oncol Rep"},{"issue":"23","key":"12_CR5","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-14-1889","volume":"20","author":"FT Awan","year":"2014","unstructured":"Awan FT, Byrd JC (2014) New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res 20(23):5869\u20135874","journal-title":"Clin Cancer Res"},{"issue":"20","key":"12_CR6","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"PM Barr","year":"2016","unstructured":"Barr PM, Saylors GB, Spurgeon SE et al (2016) Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 127(20):2411\u20132415","journal-title":"Blood"},{"issue":"1","key":"12_CR7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.12498","volume":"163","author":"J Bodo","year":"2013","unstructured":"Bodo J, Zhao X, Sharma A et al (2013) The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br J Haematol 163(1):72\u201380","journal-title":"Br J Haematol"},{"issue":"6","key":"12_CR8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1078155216653705","volume":"23","author":"JB Bossaer","year":"2017","unstructured":"Bossaer JB, Chakraborty K (2017) Drug interaction between idelalisib and diazepam resulting in altered mental status and respiratory failure. J Oncol Pharm Pract 23(6):470\u2013472","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"12_CR9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.seminoncol.2016.02.004","volume":"43","author":"JR Brown","year":"2016","unstructured":"Brown JR (2016) The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Semin Oncol 43(2):260\u2013264","journal-title":"Semin Oncol"},{"issue":"22","key":"12_CR10","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE et al (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood 123(22):3390\u20133397","journal-title":"Blood"},{"issue":"4","key":"12_CR11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrclinonc.2014.42","volume":"11","author":"JA Burger","year":"2014","unstructured":"Burger JA, Okkenhaug K (2014) Haematological cancer: idelalisib-targeting PI3K\u03b4 in patients with B-cell malignancies. Nat Rev Clin Oncol 11(4):184\u2013186","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"12_CR12","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425\u20132437","journal-title":"N Engl J Med"},{"issue":"4","key":"12_CR13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.18632\/oncotarget.1484","volume":"5","author":"RT Burke","year":"2014","unstructured":"Burke RT, Meadows S, Loriaux MM et al (2014) A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget 5(4):908\u2013915","journal-title":"Oncotarget"},{"issue":"27","key":"12_CR14","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2014.55.8262","volume":"32","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM (2014a) Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol 32(27):3039\u20133047","journal-title":"J Clin Oncol"},{"issue":"3","key":"12_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S et al (2014b) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"6","key":"12_CR16","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.3892\/or.2016.5176","volume":"36","author":"Y Chen","year":"2016","unstructured":"Chen Y, Zhou Q, Zhang L et al (2016) Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells. Oncol Rep 36(6):3643\u20133650","journal-title":"Oncol Rep"},{"issue":"23","key":"12_CR17","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","volume":"30","author":"BD Cheson","year":"2012","unstructured":"Cheson BD, Byrd JC, Rai KR et al (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30(23):2820\u20132822","journal-title":"J Clin Oncol"},{"issue":"8","key":"12_CR18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804\u2013815","journal-title":"N Engl J Med"},{"issue":"5","key":"12_CR19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PPO.0b013e31826c5810","volume":"18","author":"MY Choi","year":"2012","unstructured":"Choi MY, Kipps TJ (2012) Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 18(5):404\u2013410","journal-title":"Cancer J"},{"issue":"10","key":"12_CR20","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutre","year":"2015","unstructured":"Coutre SE, Barrientos JC, Brown JR et al (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 56(10):2779\u20132786","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"12_CR21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.clinthera.2013.08.004","volume":"35","author":"AV Danilov","year":"2013","unstructured":"Danilov AV (2013) Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther 35(9):1258\u20131270","journal-title":"Clin Ther"},{"issue":"17","key":"12_CR22","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","volume":"120","author":"MS Davids","year":"2012","unstructured":"Davids MS, Deng J, Wiestner A et al (2012) Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 120(17):3501\u20133509","journal-title":"Blood"},{"issue":"2","key":"12_CR23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2016000976","volume":"1","author":"S Vos de","year":"2016","unstructured":"de Vos S, Wagner-Johnston N, Coutre S et al (2016) Combinations of idelalisib with rituximab and\/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. Blood Adv 1(2):122\u2013131","journal-title":"Blood Adv"},{"issue":"7415","key":"12_CR24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","volume":"489","author":"M Duhren-von Minden","year":"2012","unstructured":"Duhren-von Minden M, Ubelhart R, Schneider D et al (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489(7415):309\u2013312","journal-title":"Nature"},{"issue":"7","key":"12_CR25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928\u2013942","journal-title":"Lancet Oncol"},{"key":"12_CR26","doi-asserted-by":"crossref","unstructured":"Eyre TA, Osborne WL, Gallop-Evans E et al (2017) Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. Br J Haematol","DOI":"10.1111\/bjh.14898"},{"issue":"1","key":"12_CR27","doi-asserted-by":"crossref","first-page":"e2016011","DOI":"10.4084\/mjhid.2016.011","volume":"8","author":"L Falchi","year":"2016","unstructured":"Falchi L, Baron JM, Orlikowski CA, Ferrajoli A (2016) BCR signaling inhibitors: an overview of toxicities associated with ibrutinib and idelalisib in patients with chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis 8(1):e2016011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"12","key":"12_CR28","doi-asserted-by":"crossref","first-page":"e83830","DOI":"10.1371\/journal.pone.0083830","volume":"8","author":"S Fiorcari","year":"2013","unstructured":"Fiorcari S, Brown WS, McIntyre BW et al (2013) The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One 8(12):e83830","journal-title":"PLoS One"},{"issue":"2","key":"12_CR29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM et al (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127(2):208\u2013215","journal-title":"Blood"},{"issue":"22","key":"12_CR30","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP et al (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123(22):3406\u20133413","journal-title":"Blood"},{"issue":"4","key":"12_CR31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/pr.110.004051","volume":"64","author":"JG Foster","year":"2012","unstructured":"Foster JG, Blunt MD, Carter E, Ward SG (2012) Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory\/autoimmune diseases and hematological malignancies. Pharmacol Rev 64(4):1027\u20131054","journal-title":"Pharmacol Rev"},{"issue":"11","key":"12_CR32","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMe1400055","volume":"370","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Cantley LC (2014) Idelalisib\u2014a PI3K\u03b4 inhibitor for B-cell cancers. N Engl J Med 370(11):1061\u20131062","journal-title":"N Engl J Med"},{"issue":"7","key":"12_CR33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/2159-8290.CD-11-0249","volume":"1","author":"DA Fruman","year":"2011","unstructured":"Fruman DA, Rommel C (2011) PI3K\u03b4 inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 1(7):562\u2013572","journal-title":"Cancer Discov"},{"issue":"11","key":"12_CR34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997\u20131007","journal-title":"N Engl J Med"},{"issue":"2","key":"12_CR35","doi-asserted-by":"crossref","first-page":"232470961771146","DOI":"10.1177\/2324709617711463","volume":"5","author":"JG Gabriel","year":"2017","unstructured":"Gabriel JG, Kapila A, Gonzalez-Estrada A (2017) A severe case of cutaneous adverse drug reaction secondary to a novice drug: idelalisib. J Investig Med High Impact Case Rep 5(2):2324709617711463","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"3","key":"12_CR36","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1470-2045(14)70052-X","volume":"15","author":"JA Gilbert","year":"2014","unstructured":"Gilbert JA (2014) Idelalisib: targeting PI3K\u03b4 in B-cell malignancies. Lancet Oncol 15(3):e108","journal-title":"Lancet Oncol"},{"issue":"9","key":"12_CR37","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/ijc.29579","volume":"137","author":"E Gockeritz","year":"2015","unstructured":"Gockeritz E, Kerwien S, Baumann M et al (2015) Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer 137(9):2234\u20132242","journal-title":"Int J Cancer"},{"issue":"5","key":"12_CR38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","volume":"28","author":"AK Gopal","year":"2017","unstructured":"Gopal AK, Fanale MA, Moskowitz CH et al (2017a) Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma. Ann Oncol 28(5):1057\u20131063","journal-title":"Ann Oncol"},{"issue":"11","key":"12_CR39","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S et al (2014) PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008\u20131018","journal-title":"N Engl J Med"},{"issue":"22","key":"12_CR40","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","volume":"129","author":"AK Gopal","year":"2017","unstructured":"Gopal AK, Kahl BS, Flowers CR et al (2017b) Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 129(22):3037\u20133039","journal-title":"Blood"},{"issue":"11","key":"12_CR41","first-page":"821","volume":"31","author":"IB Greenwell","year":"2017","unstructured":"Greenwell IB, Ip A, Cohen JB (2017) PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park) 31(11):821\u2013828","journal-title":"Oncology (Williston Park)"},{"key":"12_CR42","doi-asserted-by":"crossref","unstructured":"Gupta A, Li HC (2016) Idelalisib-induced pneumonitis. BMJ Case Rep 2016","DOI":"10.1136\/bcr-2016-216343"},{"issue":"9747","key":"12_CR43","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164\u20131174","journal-title":"Lancet"},{"issue":"2","key":"12_CR44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12328-016-0707-y","volume":"10","author":"MB Hammami","year":"2017","unstructured":"Hammami MB, Al-Taee A, Meeks M et al (2017) Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease. Clin J Gastroenterol 10(2):142\u2013146","journal-title":"Clin J Gastroenterol"},{"issue":"4","key":"12_CR45","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1183\/13993003.01670-2015","volume":"47","author":"E Haustraete","year":"2016","unstructured":"Haustraete E, Obert J, Diab S et al (2016) Idelalisib-related pneumonitis. Eur Respir J 47(4):1280\u20131283","journal-title":"Eur Respir J"},{"issue":"2","key":"12_CR46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y, Perez-Galan P, Liu D et al (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-\u03baB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117(2):563\u2013574","journal-title":"Blood"},{"issue":"12","key":"12_CR47","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SE Herman","year":"2010","unstructured":"Herman SE, Gordon AL, Wagner AJ et al (2010) Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116(12):2078\u20132088","journal-title":"Blood"},{"issue":"2","key":"12_CR48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/1078155215572933","volume":"22","author":"YG Hewett","year":"2016","unstructured":"Hewett YG, Uprety D, Shah BK (2016) Idelalisib\u2014a PI3K\u03b4 targeting agent for B-cell malignancies. J Oncol Pharm Pract 22(2):284\u2013288","journal-title":"J Oncol Pharm Pract"},{"issue":"13","key":"12_CR49","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M et al (2011) The phosphoinositide 3\u2019-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603\u20133612","journal-title":"Blood"},{"key":"12_CR50","doi-asserted-by":"crossref","unstructured":"Huilaja L, Lindgren O, Soronen M, Siitonen T, Tasanen K (2017) A slowly developed severe cutaneous adverse reaction to idelalisib. J Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.14700"},{"issue":"9","key":"12_CR51","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2009-06-222943","volume":"116","author":"H Ikeda","year":"2010","unstructured":"Ikeda H, Hideshima T, Fulciniti M et al (2010) PI3K\/p110\u03b4 is a novel therapeutic target in multiple myeloma. Blood 116(9):1460\u20131468","journal-title":"Blood"},{"issue":"3","key":"12_CR52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/14728214.2014.929663","volume":"19","author":"S Jahangiri","year":"2014","unstructured":"Jahangiri S, Friedberg J, Barr P (2014) Emerging protein kinase inhibitors for the treatment of non-Hodgkin\u2019s lymphoma. Expert Opin Emerg Drugs 19(3):367\u2013383","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"12_CR53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.blre.2015.12.002","volume":"30","author":"N Jain","year":"2016","unstructured":"Jain N, O\u2019Brien S (2016) Targeted therapies for CLL: practical issues with the changing treatment paradigm. Blood Rev 30(3):233\u2013244","journal-title":"Blood Rev"},{"key":"12_CR54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","volume":"59","author":"F Janku","year":"2017","unstructured":"Janku F (2017) Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients. Cancer Treat Rev 59:93\u2013101","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"12_CR55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/joim.12600","volume":"282","author":"M Jerkeman","year":"2017","unstructured":"Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L (2017) Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med 282(5):415\u2013428","journal-title":"J Intern Med"},{"issue":"1","key":"12_CR56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.beha.2016.08.004","volume":"29","author":"D Jeyakumar","year":"2016","unstructured":"Jeyakumar D, O\u2019Brien S (2016) B cell receptor inhibition as a target for CLL therapy. Best Pract Res Clin Haematol 29(1):2\u201314","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"12_CR57","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcph.495","volume":"55","author":"F Jin","year":"2015","unstructured":"Jin F, Robeson M, Zhou H et al (2015) Clinical drug interaction profile of idelalisib in healthy subjects. J Clin Pharmacol 55(8):909\u2013919","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"12_CR58","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","volume":"4","author":"JA Jones","year":"2017","unstructured":"Jones JA, Robak T, Brown JR et al (2017) Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol 4(3):e114\u2013e126","journal-title":"Lancet Haematol"},{"issue":"22","key":"12_CR59","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR et al (2014) A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood 123(22):3398\u20133405","journal-title":"Blood"},{"issue":"1","key":"12_CR60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11523-015-0359-8","volume":"10","author":"GM Keating","year":"2015","unstructured":"Keating GM (2015) Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin\u2019s lymphoma. Target Oncol 10(1):141\u2013151","journal-title":"Target Oncol"},{"issue":"2","key":"12_CR61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson BL, Kasar SN, Matos TR et al (2016) Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128(2):195\u2013203","journal-title":"Blood"},{"issue":"2","key":"12_CR62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SE et al (2011) CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2):591\u2013594","journal-title":"Blood"},{"issue":"4","key":"12_CR63","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/14737140.2015.1014807","volume":"15","author":"S Liewer","year":"2015","unstructured":"Liewer S, Huddleston AN (2015) Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients. Expert Rev Anticancer Ther 15(4):453\u2013464","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"12_CR64","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","volume":"39","author":"CY Louie","year":"2015","unstructured":"Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol 39(12):1653\u20131660","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"12_CR65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11899-012-0142-1","volume":"8","author":"IM Macias-Perez","year":"2013","unstructured":"Macias-Perez IM, Flinn IW (2013) GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr Hematol Malig Rep 8(1):22\u201327","journal-title":"Curr Hematol Malig Rep"},{"key":"12_CR66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-015-0157-x","volume":"8","author":"R Maffei","year":"2015","unstructured":"Maffei R, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R (2015) Targeting neoplastic B cells and harnessing microenvironment: the \u201cdouble face\u201d of ibrutinib and idelalisib. J Hematol Oncol 8:60","journal-title":"J Hematol Oncol"},{"issue":"7","key":"12_CR67","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1078155216656929","volume":"23","author":"BL Marini","year":"2017","unstructured":"Marini BL, Samanas L, Perissinotti AJ (2017) Expanding the armamentarium for chronic lymphocytic leukemia: a review of novel agents in the management of chronic lymphocytic leukemia. J Oncol Pharm Pract 23(7):502\u2013517","journal-title":"J Oncol Pharm Pract"},{"issue":"14","key":"12_CR68","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A (2014) Idelalisib: first global approval. Drugs 74(14):1701\u20131707","journal-title":"Drugs"},{"issue":"8","key":"12_CR69","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","volume":"119","author":"SA Meadows","year":"2012","unstructured":"Meadows SA, Vega F, Kashishian A et al (2012) PI3K\u03b4 inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119(8):1897\u20131900","journal-title":"Blood"},{"issue":"7","key":"12_CR70","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","volume":"21","author":"BW Miller","year":"2015","unstructured":"Miller BW, Przepiorka D, de Claro RA et al (2015) FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res 21(7):1525\u20131529","journal-title":"Clin Cancer Res"},{"issue":"10","key":"12_CR71","doi-asserted-by":"crossref","first-page":"16259","DOI":"10.18632\/oncotarget.15180","volume":"8","author":"P Modi","year":"2017","unstructured":"Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V (2017) Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget 8(10):16259\u201316274","journal-title":"Oncotarget"},{"issue":"5","key":"12_CR72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17474086.2017.1313108","volume":"10","author":"S Molica","year":"2017","unstructured":"Molica S (2017) Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future. Expert Rev Hematol 10(5):425\u2013432","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"12_CR73","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.3109\/10428194.2015.1061193","volume":"56","author":"F Morabito","year":"2015","unstructured":"Morabito F, Gentile M, Seymour JF, Polliack A (2015) Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. Leuk Lymphoma 56(12):3250\u20133256","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"12_CR74","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-11-2308","volume":"18","author":"V Nardi","year":"2012","unstructured":"Nardi V, Song Y, Santamaria-Barria JA et al (2012) Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res 18(5):1227\u20131236","journal-title":"Clin Cancer Res"},{"key":"12_CR75","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-4614-8051-8_12","volume":"792","author":"CU Niemann","year":"2013","unstructured":"Niemann CU, Jones J, Wiestner A (2013) Towards targeted therapy of chronic lymphocytic leukemia. Adv Exp Med Biol 792:259\u2013291","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"12_CR76","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","volume":"23","author":"CU Niemann","year":"2013","unstructured":"Niemann CU, Wiestner A (2013) B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 23(6):410\u2013421","journal-title":"Semin Cancer Biol"},{"issue":"25","key":"12_CR77","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","volume":"126","author":"SM O\u2019Brien","year":"2015","unstructured":"O\u2019Brien SM, Lamanna N, Kipps TJ et al (2015) A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood 126(25):2686\u20132694","journal-title":"Blood"},{"issue":"45","key":"12_CR78","doi-asserted-by":"crossref","first-page":"16882","DOI":"10.1073\/pnas.0607984103","volume":"103","author":"JS Oak","year":"2006","unstructured":"Oak JS, Deane JA, Kharas MG et al (2006) Sjogren\u2019s syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc Natl Acad Sci U S A 103(45):16882\u201316887","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"12_CR79","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","volume":"3","author":"K Okkenhaug","year":"2003","unstructured":"Okkenhaug K, Vanhaesebroeck B (2003) PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3(4):317\u2013330","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"12_CR80","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/15384047.2014.1002369","volume":"16","author":"TC Okoli","year":"2015","unstructured":"Okoli TC, Peer CJ, Dunleavy K, Figg WD (2015) Targeted PI3K\u03b4 inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma. Cancer Biol Ther 16(2):204\u2013206","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"12_CR81","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","volume":"177","author":"DT Patton","year":"2006","unstructured":"Patton DT, Garden OA, Pearce WP et al (2006) Cutting edge: the phosphoinositide 3-kinase p110\u03b4 is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 177(10):6598\u20136602","journal-title":"J Immunol"},{"issue":"3","key":"12_CR82","doi-asserted-by":"crossref","first-page":"e17359","DOI":"10.1371\/journal.pone.0017359","volume":"6","author":"DT Patton","year":"2011","unstructured":"Patton DT, Wilson MD, Rowan WC, Soond DR, Okkenhaug K (2011) The PI3K p110\u03b4 regulates expression of CD38 on regulatory T cells. PLoS One 6(3):e17359","journal-title":"PLoS One"},{"issue":"6","key":"12_CR83","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.seminoncol.2016.11.011","volume":"43","author":"G Pongas","year":"2016","unstructured":"Pongas G, Cheson BD (2016) PI3K signaling pathway in normal B cells and indolent B-cell malignancies. Semin Oncol 43(6):647\u2013654","journal-title":"Semin Oncol"},{"key":"12_CR84","unstructured":"Pula A, Stawiski K, Braun M, Iskierka-Jazdzewska E, Robak T (2017) Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed\/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. Leuk Lymphoma 1\u201311"},{"key":"12_CR85","first-page":"256","volume":"3","author":"KD Puri","year":"2012","unstructured":"Puri KD, Gold MR (2012) Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol 3:256","journal-title":"Front Immunol"},{"key":"12_CR86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-015-0165-x","volume":"8","author":"KR Rai","year":"2015","unstructured":"Rai KR (2015) Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol 8:85","journal-title":"J Hematol Oncol"},{"issue":"4","key":"12_CR87","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","volume":"102","author":"G Salles","year":"2017","unstructured":"Salles G, Schuster SJ, de Vos S et al (2017) Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica 102(4):e156\u2013e159","journal-title":"Haematologica"},{"issue":"7","key":"12_CR88","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clml.2015.02.019","volume":"15","author":"DS Sanford","year":"2015","unstructured":"Sanford DS, Wierda WG, Burger JA, Keating MJ, O\u2019Brien SM (2015) Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk 15(7):385\u2013391","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"12_CR89","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40265-016-0565-4","volume":"76","author":"T Seiler","year":"2016","unstructured":"Seiler T, Hutter G, Dreyling M (2016) The emerging role of PI3K inhibitors in the treatment of hematological malignancies: preclinical data and clinical progress to date. Drugs 76(6):639\u2013646","journal-title":"Drugs"},{"key":"12_CR90","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4172\/jpb.1000291","volume":"6","author":"Q Shao","year":"2013","unstructured":"Shao Q, Byrum SD, Moreland LE et al (2013) A proteomic study of human Merkel cell carcinoma. J Proteomics Bioinform 6:275\u2013282","journal-title":"J Proteomics Bioinform"},{"issue":"3","key":"12_CR91","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2040620716636542","volume":"7","author":"J Sharman","year":"2016","unstructured":"Sharman J, Di Paolo J (2016) Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib. Ther Adv Hematol 7(3):157\u2013170","journal-title":"Ther Adv Hematol"},{"issue":"16","key":"12_CR92","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMc1507446","volume":"373","author":"MB Shiver","year":"2015","unstructured":"Shiver MB, Mahmoud F, Gao L (2015) Response to idelalisib in a patient with stage IV Merkel-cell carcinoma. N Engl J Med 373(16):1580\u20131582","journal-title":"N Engl J Med"},{"issue":"4","key":"12_CR93","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","volume":"4","author":"SM Smith","year":"2017","unstructured":"Smith SM, Pitcher BN, Jung SH et al (2017) Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the alliance for clinical trials in oncology A051201 and A051202 phase 1 trials. Lancet Haematol 4(4):e176\u2013e182","journal-title":"Lancet Haematol"},{"issue":"13","key":"12_CR94","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1074\/jbc.M114.634683","volume":"290","author":"JR Somoza","year":"2015","unstructured":"Somoza JR, Koditek D, Villasenor AG et al (2015) Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase \u03b4. J Biol Chem 290(13):8439\u20138446","journal-title":"J Biol Chem"},{"issue":"3","key":"12_CR95","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-13-0226","volume":"20","author":"E Hacken ten","year":"2014","unstructured":"ten Hacken E, Burger JA (2014) Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia\u2014focus on the B-cell receptor. Clin Cancer Res 20(3):548\u2013556","journal-title":"Clin Cancer Res"},{"issue":"3","key":"12_CR96","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","volume":"1863","author":"E Hacken ten","year":"2016","unstructured":"ten Hacken E, Burger JA (2016) Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment. Biochim Biophys Acta 1863(3):401\u2013413","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"12_CR97","first-page":"1430","volume":"71","author":"K Traynor","year":"2014","unstructured":"Traynor K (2014) Idelalisib approved for three blood cancers. Am J Health Syst Pharm 71(17):1430","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"12_CR98","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ccr.2014.02.012","volume":"25","author":"B Vanhaesebroeck","year":"2014","unstructured":"Vanhaesebroeck B, Khwaja A (2014) PI3K\u03b4 inhibition hits a sensitive spot in B cell malignancies. Cancer Cell 25(3):269\u2013271","journal-title":"Cancer Cell"},{"issue":"4","key":"12_CR99","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14656566.2017.1293655","volume":"18","author":"C Vitale","year":"2017","unstructured":"Vitale C, Griggio V, Todaro M, Salvetti C, Boccadoro M, Coscia M (2017) Magic pills: new oral drugs to treat chronic lymphocytic leukemia. Expert Opin Pharmacother 18(4):411\u2013425","journal-title":"Expert Opin Pharmacother"},{"issue":"14","key":"12_CR100","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2174\/1389450117666161013115225","volume":"18","author":"P Vyas","year":"2017","unstructured":"Vyas P, Vohora D (2017) Phosphoinositide-3-kinases as the novel therapeutic targets for the inflammatory diseases: current and future perspectives. Curr Drug Targets 18(14):1622\u20131640","journal-title":"Curr Drug Targets"},{"issue":"12","key":"12_CR101","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","volume":"39","author":"AS Weidner","year":"2015","unstructured":"Weidner AS, Panarelli NC, Geyer JT et al (2015) Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol 39(12):1661\u20131667","journal-title":"Am J Surg Pathol"},{"key":"12_CR102","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation.V2012.1.88.3801172","volume":"2012","author":"A Wiestner","year":"2012","unstructured":"Wiestner A (2012) Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012:88\u201396","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"12_CR103","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/asheducation-2014.1.125","volume":"2014","author":"A Wiestner","year":"2014","unstructured":"Wiestner A (2014) BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology Am Soc Hematol Educ Program 2014(1):125\u2013134","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"12_CR104","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","volume":"100","author":"A Wiestner","year":"2015","unstructured":"Wiestner A (2015) The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica 100(12):1495\u20131507","journal-title":"Haematologica"},{"issue":"7","key":"12_CR105","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","volume":"21","author":"Q Yang","year":"2015","unstructured":"Yang Q, Modi P, Newcomb T, Queva C, Gandhi V (2015) Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 21(7):1537\u20131542","journal-title":"Clin Cancer Res"},{"key":"12_CR106","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coph.2015.05.016","volume":"23","author":"TA Yap","year":"2015","unstructured":"Yap TA, Bjerke L, Clarke PA, Workman P (2015) Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol 23:98\u2013107","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"12_CR107","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/CCO.0000000000000213","volume":"27","author":"L Ysebaert","year":"2015","unstructured":"Ysebaert L, Feugier P, Michallet AS (2015) Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies. Curr Opin Oncol 27(5):365\u2013370","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"12_CR108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","volume":"18","author":"AD Zelenetz","year":"2017","unstructured":"Zelenetz AD, Barrientos JC, Brown JR et al (2017) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 18(3):297\u2013311","journal-title":"Lancet Oncol"},{"issue":"22","key":"12_CR109","doi-asserted-by":"crossref","first-page":"a231","DOI":"10.1182\/blood.V128.22.231.231","volume":"128","author":"AD Zelenetz","year":"2016","unstructured":"Zelenetz AD, Brown JR, Delgado J, Eradat H, Ghia P, Jacob A (2016) Updated analysis of overall survival in randomized phase III study of idelalisib in combination with bendamustine and rituximab in patients with relapsed\/refractory CLL. Blood 128(22):a231","journal-title":"Blood"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Hematology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-91439-8_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:21:23Z","timestamp":1571682083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-91439-8_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319914381","9783319914398"],"references-count":109,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-91439-8_12","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}